Influvac Tetra

B/Phuket/3073/2013‑Like Virus (B/Phuket/3073/2013, Wild Type) and Influenza Virus B/Austria/1359417/202, the active ingredients in Influvac Tetra, is a vaccine presented as a vaccine for intramuscular use. It induces immunity to protect against influenza B infection in eligible populations. GNH USA supplies Influvac Tetra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Influvac Tetra is a seasonal influenza vaccine that targets influenza B virus strains to reduce disease incidence. - Seasonal influenza: provides protection against circulating influenza B strains, lowering the risk of flu illness. - High‑risk groups: helps reduce complications in elderly, young children, and immunocompromised individuals. - Pandemic preparedness: contributes to broader community immunity against potential influenza outbreaks.

Common side effects are generally mild and resolve without intervention.

Common Side Effects: - Injection site pain: soreness or tenderness at the injection site. - Redness or swelling: localized erythema or edema. - Low‑grade fever: mild temperature rise within 24‑48 hours. - Headache: transient headache after vaccination. - Myalgia: muscle aches lasting a few days. - Fatigue: temporary tiredness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical care. - Guillain‑Barré syndrome: rare neurological disorder with muscle weakness. - High fever: temperature >39°C persisting beyond 48 hours. - Seizures: uncommon neurologic events, especially in children. - Severe allergic reaction: hives, swelling of face or throat.

Vaccination should be considered in the context of individual health status and product handling requirements. - Allergy assessment: avoid if known hypersensitivity to any vaccine component. - Pregnancy: consult a healthcare provider before administration. - Immunocompromised patients: vaccine may be less effective; discuss with clinician. - Acute illness: postpone vaccination if moderate or severe fever is present. - Age restrictions: follow approved age recommendations for the product. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines may interact with other biologics or immunomodulating agents, influencing efficacy or safety.

Major Interactions (Avoid): - Live attenuated vaccines: should not be administered concurrently. - Immunoglobulin therapy: may neutralize vaccine antigens, reducing response.

Moderate Interactions (Monitor Closely): - Antiviral medications (e.g., oseltamivir): could affect immune response timing. - Immunosuppressive drugs: may diminish vaccine effectiveness. - Febrile illness: consider delaying vaccination until recovery. - Blood products: recent transfusion may interfere with antibody development.